DK1157005T3 - 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister - Google Patents

3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister

Info

Publication number
DK1157005T3
DK1157005T3 DK00909174T DK00909174T DK1157005T3 DK 1157005 T3 DK1157005 T3 DK 1157005T3 DK 00909174 T DK00909174 T DK 00909174T DK 00909174 T DK00909174 T DK 00909174T DK 1157005 T3 DK1157005 T3 DK 1157005T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
phenylpyridine derivatives
phenylpyridine
derivatives
antagonists
Prior art date
Application number
DK00909174T
Other languages
English (en)
Inventor
Michael Boes
Guido Galley
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Thierry Godel
Torsten Hoffmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1157005T3 publication Critical patent/DK1157005T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00909174T 1999-02-24 2000-02-15 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister DK1157005T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99103503 1999-02-24
PCT/EP2000/001223 WO2000050401A1 (en) 1999-02-24 2000-02-15 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
EP00909174A EP1157005B1 (en) 1999-02-24 2000-02-15 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists

Publications (1)

Publication Number Publication Date
DK1157005T3 true DK1157005T3 (da) 2005-02-14

Family

ID=8237624

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00909174T DK1157005T3 (da) 1999-02-24 2000-02-15 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister

Country Status (33)

Country Link
US (1) US6225316B1 (da)
EP (1) EP1157005B1 (da)
JP (1) JP4068305B2 (da)
KR (1) KR100437587B1 (da)
CN (1) CN1134417C (da)
AR (1) AR029616A1 (da)
AT (1) ATE280158T1 (da)
AU (1) AU772446B2 (da)
BR (1) BR0008494A (da)
CA (1) CA2364662C (da)
CO (1) CO5140087A1 (da)
CZ (1) CZ20013047A3 (da)
DE (1) DE60015089T2 (da)
DK (1) DK1157005T3 (da)
ES (1) ES2230070T3 (da)
GC (1) GC0000183A (da)
HK (1) HK1044942B (da)
HR (1) HRP20010604A2 (da)
HU (1) HUP0200139A3 (da)
IL (2) IL144851A0 (da)
JO (1) JO2254B1 (da)
MA (1) MA26773A1 (da)
MY (1) MY122630A (da)
NO (1) NO320099B1 (da)
NZ (1) NZ513370A (da)
PL (1) PL350428A1 (da)
PT (1) PT1157005E (da)
RU (1) RU2236402C2 (da)
SI (1) SI1157005T1 (da)
TR (1) TR200102489T2 (da)
WO (1) WO2000050401A1 (da)
YU (1) YU59901A (da)
ZA (1) ZA200106371B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928222D0 (en) 1999-11-30 2000-01-26 Univ Sheffield Chiral catalysts for asymmetric acylation and related transformations
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
CN1178917C (zh) * 2000-07-14 2004-12-08 弗·哈夫曼-拉罗切有限公司 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
NZ525700A (en) * 2000-11-20 2004-12-24 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US7176322B2 (en) * 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
JP2006508061A (ja) * 2002-09-20 2006-03-09 ファイザー・プロダクツ・インク エストロゲン受容体に対するアミドおよびスルホンアミドリガンド
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
EP2774925B1 (en) 2005-11-08 2016-12-28 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP-binding cassette transporters
RU2419609C2 (ru) * 2005-11-30 2011-05-27 Зольвай Фармасьютиклз Гмбх Новые антагонисты nk1 и nk2
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
TW200906408A (en) * 2007-04-24 2009-02-16 Takeda Pharmaceutical Piperidine derivative and use thereof
WO2008141119A2 (en) 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
PL2231606T3 (pl) 2007-12-07 2013-07-31 Vertex Pharma Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
HUE031913T2 (en) 2007-12-07 2017-08-28 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
KR100943878B1 (ko) * 2008-07-11 2010-02-24 오토스테크 주식회사 디지털방식 눈부심 방지 장치 및 그 제어 방법
EP2350010B1 (en) * 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
ES2663351T3 (es) * 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
US8410107B2 (en) * 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
MX355183B (es) 2012-01-25 2018-04-09 Vertex Pharma Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
BR112016009811A2 (pt) 2013-11-08 2017-12-05 Kissei Pharmaceutical derivado de carboximetil piperidina
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR102576006B1 (ko) 2014-11-18 2023-09-06 버텍스 파마슈티칼스 인코포레이티드 고처리량 시험 고성능 액체 크로마토그래피의 수행 방법
EA201891472A1 (ru) 2015-12-22 2018-12-28 Такеда Фармасьютикал Компани Лимитед Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
CN115915941B (zh) 2020-05-06 2025-07-15 拜耳公司 作为杀真菌化合物的吡啶（硫代）酰胺
BR112022024405A2 (pt) 2020-06-04 2023-01-31 Bayer Ag Heterociclil piridinas como novos fungicidas
EP4441049A1 (en) 2021-11-30 2024-10-09 Bayer Aktiengesellschaft Bis(hetero)aryl thioether oxadiazines as fungicidal compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4174209A (en) * 1978-06-19 1979-11-13 Eli Lilly And Company Herbicidal 1-alkyl-3-phenylpyridinium salts
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
JPH0794439B2 (ja) * 1990-05-31 1995-10-11 フアイザー・インコーポレイテツド 置換ピペリジンの製造法
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69434063D1 (de) 1993-12-29 2004-11-11 Merck Sharp & Dohme Substituierte Morpholinderivate und ihre Verwendung als therapeutische Mittel
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW394773B (en) * 1995-03-24 2000-06-21 Takeda Chemical Industries Ltd Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
GC0000183A (en) 2006-03-29
AU772446B2 (en) 2004-04-29
DE60015089D1 (de) 2004-11-25
EP1157005A1 (en) 2001-11-28
AR029616A1 (es) 2003-07-10
NO320099B1 (no) 2005-10-24
NZ513370A (en) 2004-02-27
CN1134417C (zh) 2004-01-14
CN1341100A (zh) 2002-03-20
MY122630A (en) 2006-04-29
HK1044942B (zh) 2004-05-28
YU59901A (sh) 2005-07-19
US6225316B1 (en) 2001-05-01
SI1157005T1 (en) 2005-02-28
PL350428A1 (en) 2002-12-16
HUP0200139A3 (en) 2003-01-28
JO2254B1 (en) 2004-10-07
JP4068305B2 (ja) 2008-03-26
WO2000050401A1 (en) 2000-08-31
NO20014098L (no) 2001-08-23
KR20010102347A (ko) 2001-11-15
ATE280158T1 (de) 2004-11-15
IL144851A0 (en) 2002-06-30
HRP20010604A2 (en) 2002-08-31
IL144851A (en) 2006-08-20
DE60015089T2 (de) 2006-02-16
EP1157005B1 (en) 2004-10-20
CO5140087A1 (es) 2002-03-22
CZ20013047A3 (cs) 2002-02-13
ES2230070T3 (es) 2005-05-01
BR0008494A (pt) 2002-02-05
TR200102489T2 (tr) 2002-04-22
MA26773A1 (fr) 2004-12-20
ZA200106371B (en) 2002-11-04
AU3154900A (en) 2000-09-14
CA2364662A1 (en) 2000-08-31
PT1157005E (pt) 2005-02-28
JP2002537382A (ja) 2002-11-05
KR100437587B1 (ko) 2004-06-30
CA2364662C (en) 2009-10-20
HK1044942A1 (en) 2002-11-08
HUP0200139A2 (en) 2002-06-29
RU2236402C2 (ru) 2004-09-20
NO20014098D0 (no) 2001-08-23

Similar Documents

Publication Publication Date Title
NO20014098D0 (no) 3-fenylpyridinderivater og anvendelse derav som NK-1 reseptor antagonister
DK1035115T3 (da) 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
NO20013809D0 (no) Indolderivater og anvendelse derav som MCP-1 antagonister
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20021689D0 (no) 5-rings heterosykliske derivater, fremstilling derav og anvendelse som medikamenter
NO20031952L (no) 3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
NO20021719D0 (no) 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament
DK1345937T3 (da) Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister
NO20043064L (no) 1-alkyl-1-azoniabisyklo [2.2.2] oktankarbamatderivater og anvendelse av disse som muskarine reseptorantagonister
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
DK0901470T3 (da) Indolderivater egnede som endothelinreceptorantagonister
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
NO996115D0 (no) Azetidinylpropylpiperidin-derivater, intermediater og anvendelse som tachykinin-antagonister
NO20025640L (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptorantagonister
NO995482D0 (no) Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister
DK1335906T3 (da) Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
NO20025762D0 (no) Bicykliske cykloheksylaminer og anvendelse derav som NMDA- reseptorantagonister
NO20023146D0 (no) Substituerte fenyl-piperazinderivater, deres fremstilling og anvendelse
DK1296961T3 (da) 1,4-diazepan-2,5-dionderivater og anvendelse deraf som NK-1-receptorantagonister
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
NO20014224L (no) 4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2- pyridyl-pyrimidinderivater, fremstilling derav og anvendelse somendotelin reseptor antagonister
NO992976L (no) Heterocykliske karboksylsyre-derivater, fremstilling og anvendelse derav som endothelinreseptor-antagonister
NO20043799L (no) 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
AUPQ570100A0 (en) Beta-alanine derivatives and their use as receptor antagonists